A novel mutation in the FcγRIIIA gene (CD16) results in active natural killer cells lacking CD16

Autoimmunity

Volumn 31, Issue 4, 1999, Pages 265-271

  Takeuchi, Tohru ^a   Nakagawa, Toshimasa ^a   Ikemoto, Toshiyuki ^a   Sasaki, Masako ^a   Makino, Shigeki ^a   Shimizu, Akira ^a   Ohsawa, Nakaaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

CD16; Fc RIIIA; Natural killer cells

Indexed keywords

LYMPHOCYTE SURFACE MARKER; MEMBRANE PROTEIN; FC RECEPTOR;

ADULT; ARTICLE; CASE REPORT; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPESTHESIA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; POLYNEUROPATHY; CYTOTOXICITY; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

ADULT; BASE SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; KILLER CELLS, NATURAL; MOLECULAR SEQUENCE DATA; MUTATION; POLYNEUROPATHIES; RECEPTORS, IGG;

EID: 0033237385     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939908994072     Document Type: Article

References (31)

1. Robertson, M.J. and Ritz, J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-38.
2. Trinchieri, G. Biology of natural killer cells. Adv. Immunol. 1989; 47: 187-376.
3. Biron, C.A., Byron, K.S. and Sullivan, J.L. Severe herpes virus infections in an adolescent without natural killer cells. N. Engl. J. Med. 1989; 320: 1731-5.
4. Ballas, Z.K., Turner, J.M., Turner, D.A., Goetzman, E.A. and Kemp, J.D. A patient with simultaneous absence of "classical" natural killer cells (CD3 , CD16+, and NKHI+) and expansion of CD3+, CD4 , CD8+, NKHI+ subset. J. Allergy Clin. Immunol. 1990; 85: 453-9.
5. Lanier, L.L., Testi, R., Bindl, J. and Phillips, J.H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural adhesion molecule. J. Exp. Med. 1989; 169: 2233-8.
6. Lanier, L.L., Chang, C., Azuma, M., Ruitenberg, J.J., Hemperly, J.J. and Phillips, J.H. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J. Immunol. 1991; 146: 4421-6.
7. Gherman, M., Manciulea, M., Bancu, A.C., Sulica, A., Stanworth, D.R. and Herberman, R.B. Regulation of human natural cytotoxity by IgG. I. Characterization of the structural site on monomeric IgG responsible for inhibiting natural killer cell activity. Mol. Immunol. 1987; 24: 743-50.
8. Bonnema, J.D., Karnitz, L.M., Schoon, R.A., Abraham, R.T. and Leibson, P.J. Fc receptor stimulation of phosphatidylinositol 3-kinase in natural killer cells is associated with protein kinase C-independent granule release and cell-mediated cytotoxicity. J. Exp. Med. 1994; 180: 1427-35.
9. Selvaraj, P. Carpen, O., Hibbs, M.L. and Springer, T.A. Natural killer cell and granulocyte Fcγ receptor III (CD16) differ in membrane anchor and signal transduction. J. Immunol. 1989; 143: 3283-8.
10. Van de Winkel, J.G.J. and Anderson, C.L. Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 1991; 49: 511-24.
11. Ravetch, J.V. and Perussia, B. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 1989; 170: 481-97.
12. Selvaraj, P., Rosse, W.F., Silber, R. and Springer, T.A. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333: 565-7.
13. de Haas, M., Koene, H.R., Kleijer, M., de Vries, E., Simsek, S., van Tol, M.J.D. et al. A triallelic Fcγ receptor type III A polymorphism influences the binding of human IgG by NK cell FcγRIIIA. J. Immunol. 1996; 156: 2948-55.
14. Jawahar, S., Moody, C., Chan, M., Finberg, R., Geha, R. and Chatila, T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 1996; 103: 408-13.
15. de Vries, E., Koene, H.R., Vossen, J.M., Gratama, J.W., von dem Borne, A.E.G.K., Waaijer, J.L.M. et al. Identification of an unusual Fcγ receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88: 3022-7.
16. Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K. et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 1997; 100: 1059-70.
17. Wigzell, H. and Ramstedt, U. Natural killer cells. In: D. Weir, L.A. Herzenberg, C. Blackwell and L.A. Herzenberg (Ed.), Handbook of Experimental Immunology. Vol. 2 Oxford: Blackwell, 1986, pp. 60.1-60.11.
18. Hanaumi, K., Hinuma, S. and Kumagai, K. ADCC. In: S. Migita, S. Konda, T. Honjo and T. Hamaoka (Ed.). Experimental Manual of Immunology. Tokyo: Nankodo Co. 1995, pp. 718-23.
19. Farrel Jr., R.E. Protocol: Guunidinium CsCl isopycnic purification of RNA. In: RNA Methodologies. San Diego: Academic Press, 1993, pp. 58-62.
20. Koene, H.R., Kleijer, M., Algra, H., Roos, D., von dem Borne, A.E.G.K. and de Baas, Masja. FcγRIIIa-158V F polymorphism influence the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L R H phenotype. Blood 1997; 90: 1109-14.
21. Gessner, J.E., Grussenmeyer, T., Kolanur, W. and Schmidt, R.E. The human low affinity immunoglobulin G Fc receptor III-A and III-B genes. Molecular characterization of the promoter regions. J. Biol. Chem. 1995; 270: 1350-61.
22. Nagler, A., Lanier, L.L., Cwirla, S. and Phillips, J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 1989; 143: 3183-91.
23. Metes, D., Ernst, L.K., Chambers, W.H., Suliea, A., Herberman, R.B. and Morel, P.A. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcγRIIC gene. Blood 1998; 91: 2369-80.
24. Mantozioris, B.X., Berger, M.F., Sewell, W. and Zola, H. Expression of the Fc receptor for IgG (FcγRII CD32w) by human circulating T and B lymphocytes. J. Immunol. 1993; 150: 5175-84.
25. Ravetch, J.V. Fc receptors: Rubor redox. Cell 1994; 78: 553-60.
26. Van de Winkel, J.G.J. and Capel, P.J.A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993; 14: 215-21.
27. Ada, G. Twenty years into the saga of MHC-restriction. Immunol. Cell Biol. 1994; 72: 447-54.
28. Van der Pol, W.L. and van de Winkel, J.G.J. IgG receptor polymorphisms: risk factors for disease. Immunogenet. 1998; 48: 222-32.
29. Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E. and Kimberly, R. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 1997; 100: 1059-70.
30. Wainstein, E., Edberg, J., Csernok, E., Scheller, M., Hoffman, G., Keystone, E., Gross, W., Salmon, J. and Kimberly, R. FcγRIIIB alleles predict renal dysfunction in Wegener's granulomatosis (WG). Arthritis Rheum. 1996; 39: S210.
31. Duits, A.J., Bootsma, H., Derksen, R.H.W.M., Spronk, O.E., Kater, L., Kallenberg, G.G.M., Capel, P.J.A., Westerdaal, N.A.C., Spierenbury, G.T., Gmelig-Meyling, F.H.J. and van de Winkel, J.G.J. Skewed distribution of IgG Fcγ receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum. 1995; 39: 1832-6.